First interview of the #EHA25 Day 2. Dr. Litzow of @MayoClinic #mmsm #allsm Remember stop by and share your research. Hearing about your research provides patients with hope. We are located across from Coral 4!

Its always nice to hear from the basic researchers. Their successes in the lab eventually transfer to patient care. Thanks! youtu.be/VHE5-RQJnf8?... #MMsm #ASH24 #HealthTree #myeloma

Can diet change outcomes? youtu.be/ieT73JXu_kc?... #MMsm #ASH24 #myeloma

Today’s ASH highlight video is on Cevostamab-a fixed duration bispecific antibody that targets FCRH5 youtu.be/kHNBPB1S7QY?... #MMsm #ASH24 #HealthTree #myeloma

Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 youtu.be/oZfpQWdgiSc?...

Another Myeloma maintenance study- Auriga Study Subgroup Update - youtu.be/xKaOtop1fik?... #MMsm #ASH24 #HealthTree #myeloma

Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma

To treat or not to treat (HR-SMM) - Listen to @thanosdimop talk about the results of the Aquila trial #MMsm #ASH24 #HealthTree #myeloma youtu.be/C7f-cTLBBfo

Reaching MRD negativity is the goal of #myeloma treatment. The CoMMander trial used Iberdomide to achieve this in Post-ASCT patients who had residual disease after 100 days. @healthtreeorg.bsky.social #MMSM #ASH24 m.youtube.com/watch?v=MiWM...

New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session

Tri-specific Antibody #SAR442257 in RRMM and Non- Hodgkin Lymphoma #MMsm #ASH24 #HealthTree #myeloma youtu.be/7NzP-E9WnRo

There is a new CAR on the block and it’s performing exceptionally well. This is one of the many videos that is posted on the @HealthTree for Multiple Myeloma YouTube channel where our ASH coverage will be featured . #MMsm #ASH24 #HealthTree #myeloma youtu.be/sx89o8X7vvU

Excited that the results of the phase I/II trial of modakafusp alfa in patients with relapsed/refractory multiple myeloma are now published in @bloodjournal.bsky.social. This agent has a novel mechanism of action and has single-agent activity. #mmsm

Thanks for including a patient advocate on this important research project! #MMsm #ASH24 #HealthTree #myeloma

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd - Update: 12/4/24 - cc @grpetersen1 - @bdermanmd @bhemato @DrOlaLandgren @End_myeloma @HadidiSamer @jmikhaelmd @ManniMD1 @MeeraMohanMD @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @Taxkourel @VincentRK

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 26, 2024 v2 - cc @grpetersen1 - @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani et al.

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 20, 2024 - cc @grpetersen1 - @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @szusmani et al.

Who is going to #ASH24?! And who is bringing bracelets to trade?!